tirzepatide glp1 and gip Bumps humps in the success of as the first and receptor agonist Frontiers | GLP-1/GIP dual agonist

Even moderate exercise such as brisk walking for 30 minutes daily can make a significant difference

Entries were censored at the last date of the study period, or the date of GLP1-RA initiation among DDP4i users who discontinued DDP4i and started GLP1-RA

Zepbound was FDA-approved in 2023 for long-term weight management in adults with obesity (with a body mass index of 30 or higher) and overweight (with a body mass index of 27 or higher) with at least one weight-related condition, such as high blood pressure, type 2 diabetes, or high cholesterol

Importantly, GLP-1 receptor agonists are not recommended for patients with severe gastroparesis, as they may further delay gastric emptying and worsen symptoms